Eptifibatide

Platelet Aggregation Inhibitor — BLOOD AND BLOOD FORMING ORGANS

Key facts

Eptifibatide is an ofp drug in the Platelet Aggregation Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1998. DrugCentral lists 1 molecular target, including ITGB3|ITGA2B. Recorded indications include Acute coronary syndrome, NonQ wave myocardial infarction, Percutaneous coronary intervention and Unstable angina.

• Approval status: ofp (first approved 1998 by the FDA).
• Drug class: Platelet Aggregation Inhibitor.
• Molecular targets: ITGB3|ITGA2B (1 listed in DrugCentral).
• Indications: Acute coronary syndrome, NonQ wave myocardial infarction, Percutaneous coronary intervention and Unstable angina.
• ATC code: B01AC16 (Platelet aggregation inhibitors excl. heparin).
• Molecular formula: C35H49N11O9S2; molecular weight 831.97 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

• Acute coronary syndrome
• NonQ wave myocardial infarction
• Percutaneous coronary intervention
• Unstable angina

Contraindications (10)

• Acute hemorrhage
• Acute Thromboembolic Stroke
• Blood coagulation disorder
• Hemorrhagic cerebral infarction
• Hypertensive urgency
• Impaired renal function disorder
• Puncture of Noncompressible Artery
• Renal dialysis
• Surgical procedure
• Thrombocytopenic disorder

Mechanism & targets

• Established pharmacologic class: Platelet Aggregation Inhibitor

Molecular targets (1)

Target	Gene	Action	Activity
Integrin alpha-IIb/beta-3	ITGB3|ITGA2B	inhibitor	IC50 6.24

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
1999-07-01	EMA	—	GLAXOSMITHKLINE (IRELAND) LIMITED
1998-05-18	FDA	—	SCHERING

ATC classification

ATC code	Therapeutic hierarchy
B01AC16	BLOOD AND BLOOD FORMING ORGANS › ANTITHROMBOTIC AGENTS › ANTITHROMBOTIC AGENTS › Platelet aggregation inhibitors excl. heparin

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Myocardial infarction	722.9
Vascular stent thrombosis	188.8
Thrombocytopenia	134.8
Thrombosis in device	132.0
Myocardial rupture	101.8
Acute myocardial infarction	92.0
Haemorrhage	85.6
Product use in unapproved indication	76.5
Arterial thrombosis	69.5

Chemical structure

• Molecular formula: C₃₅H₄₉N₁₁O₉S₂
• Molecular weight: 831.97 g/mol
• CAS number: 188627-80-7
• InChIKey: CZKPOZZJODAYPZ-LROMGURASA-N
• PubChem CID: 448812

NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O)C(N)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Eptifibatide used for?

DrugCentral lists the following indications for Eptifibatide: Acute coronary syndrome, NonQ wave myocardial infarction, Percutaneous coronary intervention and Unstable angina.

How does Eptifibatide work?

Its molecular targets in DrugCentral include ITGB3|ITGA2B (inhibitor).

When was Eptifibatide first approved?

Eptifibatide was first approved by the FDA in 1998.

What drug class does Eptifibatide belong to?

Eptifibatide is in the Platelet Aggregation Inhibitor class.

What is the chemical formula of Eptifibatide?

Eptifibatide has the molecular formula C35H49N11O9S2 and a molecular weight of 831.97 g/mol.

Sources

• DrugCentral drug card 1040 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1174 — compound record and bioactivity
• PubChem CID 448812 — chemical identifiers
• DrugBank DB00063 — drug record
• FDA UNII NA8320J834 — substance identity
• DailyMed: FDA labels for Eptifibatide — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.